Clinical trial
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity &…
NCT00316693 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316693 |
|---|---|
| Title | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine |
| Official title | A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV-16/18 vaccine (Cervarix™), Aimmugen™ |
| Enrollment | 1,046 |
| Start date | Apr 26, 2006 |
| Primary completion | Feb 10, 2009 |
| Completion | Feb 10, 2009 |
| First posted | Apr 21, 2006 |
| Last update posted | Sep 4, 2018 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: